Copyright
©The Author(s) 2020.
World J Clin Cases. Oct 26, 2020; 8(20): 4883-4894
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4883
Published online Oct 26, 2020. doi: 10.12998/wjcc.v8.i20.4883
Figure 6 Computed tomography images showing mild improvement of the metastatic lesions and mild shrinkage of the para-tracheal tumor after 5-mo sorafenib (400 mg/d), compared to that with Lenvatinib (10 mg/d).
A and B: Lenvatinib, 10 mg/d; C and D: Sorafenib, 400 mg/d.
- Citation: Yang CH, Chen KT, Lin YS, Hsu CY, Ou YC, Tung MC. Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report. World J Clin Cases 2020; 8(20): 4883-4894
- URL: https://www.wjgnet.com/2307-8960/full/v8/i20/4883.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i20.4883